Zangari, P;
Palma, P;
Cotugno, N;
Rojo, P;
Tagarro, A;
Pepponi, I;
De Rossi, A;
... Rossi, P; + view all
(2018)
Report from the First EPIICAL (Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies) General Assembly meeting, 9-11 November 2017, Rome, Italy.
Journal of Virus Eradication
, 4
(1)
pp. 51-54.
Preview |
Text
jve-4-51.pdf - Published Version Download (101kB) | Preview |
Abstract
EPIICAL is a network of excellence concerned with a wide range of activities, including developmental research on novel disease modifying therapies (NDMTs), with the goal of achieving HIV remission. A central and timely theme of the network is the establishment of a predictive in vitro and in vivo platform to optimise the management of perinatally HIV-infected children and to inform treatment strategies (Figure 1). The EPIICAL project is a global collaboration of 27 international institutions, funded through an independent grant by ViiV Healthcare. Rome, Italy, hosted the first EPIICAL General Assembly (9–11 November 2017). Over 70 participants from 12 countries were brought together to discuss the updates of the first 18 months of the project, future strategies and perspectives. The meeting, chaired by Paolo Rossi (OPBG) and Carlo Giaquinto (Penta Foundation), included lectures by invited speakers, roundtable discussions and oral presentations by each work group. This conference report captures much of the ongoing research and the major themes discussed during the three-day meeting.
Archive Staff Only
 |
View Item |
